Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kiyomitsu, Katsumata"'
Autor:
Kiyomitsu Katsumata, Jun Ishihara, Kazuto Fukunaga, Ako Ishihara, Eiji Yuba, Erica Budina, Jeffrey A. Hubbell
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background Although disease in a majority of rheumatoid arthritis (RA) patients is often initially limited to one or a few joints, currently approved medications including anti-tumor necrosis factor-α antibody (α-TNF) are injected systemic
Externí odkaz:
https://doaj.org/article/5d877f7d012a4cd8b7a0f1b126dce533
Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes
Publikováno v:
Molecules, Vol 16, Iss 9, Pp 7210-7223 (2011)
ASP2151 is a herpesvirus helicase-primase inhibitor with antiviral activity against varicella zoster virus and herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). Here, we examined the potency and efficacy of ASP2151 against HSV in vitro and in vivo.
Externí odkaz:
https://doaj.org/article/6f6a95645a4d4d7f9182203bc6149f62
Autor:
Jun Ishihara, Kiyomitsu Katsumata, Eiji Yuba, Ako Ishihara, Jeffrey A. Hubbell, Peyman Hosseinchi, Melody A. Swartz, Joseph W. Reda, Aslan Mansurov, Elyse A. Watkins, Andrew C Tremain, Ani Solanki, Aaron T. Alpar, Erica Budina, Lea Maillat, Takahiro Kageyama, Mindy Nguyen
Interleukin-4 (IL-4) suppresses the development of multiple sclerosis in a murine model of experimental autoimmune encephalomyelitis (EAE). Here, we show that, in mice with EAE, the accumulation and persistence in the lymph nodes and spleen of a syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc2c54ec773f6e2b7177fa901442dd6
http://hdl.handle.net/10044/1/83460
http://hdl.handle.net/10044/1/83460
Publikováno v:
Biochemical Pharmacology. 158:201-206
Existing treatments have limited efficacy against severe infection associated with herpes simplex virus (HSV) and herpes zoster virus (VZV), particularly in immunocompromized patients and those with multidermatomal infection. This issue, along with i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::361976947d5bb10d53400582c90ab2d0
https://doi.org/10.1016/j.bcp.2018.10.024
https://doi.org/10.1016/j.bcp.2018.10.024
Autor:
Katsunori Yanagihara, Junichi Matsuda, Kosuke Kosai, Kiyomitsu Katsumata, Norihito Kaku, Norihiko Akamatsu
Publikováno v:
Journal of Infection and Chemotherapy. 24:492-495
The narrow-spectrum macrocyclic antibiotic fidaxomicin is approved for treatment of Clostridium difficile infection in many countries and is currently under evaluation in Japan for this indication. This study was conducted to evaluate the effects of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d81777531731074480d44f8e597557
https://doi.org/10.1016/j.jiac.2017.12.006
https://doi.org/10.1016/j.jiac.2017.12.006
Autor:
Ako, Ishihara, Jun, Ishihara, Elyse A, Watkins, Andrew C, Tremain, Mindy, Nguyen, Ani, Solanki, Kiyomitsu, Katsumata, Aslan, Mansurov, Erica, Budina, Aaron T, Alpar, Peyman, Hosseinchi, Lea, Maillat, Joseph W, Reda, Takahiro, Kageyama, Melody A, Swartz, Eiji, Yuba, Jeffrey A, Hubbell
Publikováno v:
Nature biomedical engineering. 5(5)
Interleukin-4 (IL-4) suppresses the development of multiple sclerosis in a murine model of experimental autoimmune encephalomyelitis (EAE). Here, we show that, in mice with EAE, the accumulation and persistence in the lymph nodes and spleen of a syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::68c43e02287c4911b22431ceb429eeff
https://pubmed.ncbi.nlm.nih.gov/33093659
https://pubmed.ncbi.nlm.nih.gov/33093659
Autor:
Ako Ishihara, Kiyomitsu Katsumata, Erica Budina, Eiji Yuba, Jun Ishihara, Kazuto Fukunaga, Jeffrey A. Hubbell
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
BackgroundAlthough disease in a majority of rheumatoid arthritis (RA) patients is often initially limited to one or a few joints, currently approved medications including anti-tumor necrosis factor-α antibody (α-TNF) are injected systemically. Give
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6d76fa5a8571e1d3c20aed567e8f15e
http://hdl.handle.net/10044/1/83367
http://hdl.handle.net/10044/1/83367
Autor:
Eiji Yuba, Jeffrey A. Hubbell, Michal M. Raczy, Ako Ishihara, Jun Ishihara, Kiyomitsu Katsumata, Aslan Mansurov
Publikováno v:
Nature Reviews Rheumatology
Science Advances
Science Advances
Inflammation targeting through collagen affinity improves antibody therapeutic ability.
Enhancing the therapeutic efficacy of drugs for inflammatory diseases is of high demand. One possible approach is targeting drugs to the extracellular matrix
Enhancing the therapeutic efficacy of drugs for inflammatory diseases is of high demand. One possible approach is targeting drugs to the extracellular matrix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5343d0df93a728ca917a7fdf9caa06da
Autor:
Ikuko Nakamura, Kiyomitsu Katsumata, Hikaru Mitori, Shinobu Takeda, Satoru Matsumoto, Keisuke Ohsumi, Souichiro Akamatsu, Toru Nakai
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Current therapies against invasive pulmonary aspergillosis (IPA) have a limited cure rate. Given that a delay in treatment initiation may be fatal, a new drug with rapid-onset and potent fungicidal activity is needed. The novel cyclic hexapeptide ASP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11a1aca61d68e937d4997e9925f308a6
https://doi.org/10.1128/aac.02689-18
https://doi.org/10.1128/aac.02689-18
Autor:
John-Michael Williford, Koichi Sasaki, Melody A. Swartz, Michal M. Raczy, Laura T. Gray, Hiroyuki Abe, Peyman Hosseinchi, Mariko Yasui, Steve S. Lee, Jeffrey A. Hubbell, Kiyomitsu Katsumata, Aslan Mansurov, Ako Ishihara, Lambert Potin, Stephen J. Kron, Masashi Fukayama, Jun Ishihara, Kazuto Fukunaga
Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2da2d838c5c4b7788b32d5e26d9fd60
https://europepmc.org/articles/PMC6541444/
https://europepmc.org/articles/PMC6541444/